key: cord-0805481-vh9g9x21
authors: Sekar, Arjun; Campbell, Ruth; Tabbara, Jad; Rastogi, Prerna
title: ANCA GLOMERULONEPHRITIS POST MODERNA COVID-19 VACCINATION
date: 2021-05-31
journal: Kidney Int
DOI: 10.1016/j.kint.2021.05.017
sha: 43bfb86d086a3418711aa092257b87c94b12f1cf
doc_id: 805481
cord_uid: vh9g9x21

nan

A 52-year-old white male presented with headache and weakness, 2 weeks after receiving his second dose of the Moderna (mRNA-1273) vaccine on April 15 th , 2021. Headache started the day after his second vaccination and was associated with weakness. Vitals were stable and physical examination was unremarkable. Past medical history included hypertension, treated with amlodipine. He had no allergies and denied illicit drug use.

Initial labs showed a creatinine of 8.41 mg/dl (baseline: 1.11 mg/dL, eight months prior), BUN 82 mg/dl, sodium 129 meq/L, potassium 5.0 meq/L, bicarbonate 21 meq/L and hemoglobin 14.6 g/dL. Toxicology screen was negative. Urinalysis had 1+ proteinuria and microscopic hematuria with dysmorphic red blood cells. Renal ultrasound revealed no hydronephrosis. Intravenous hydration was initiated. Additional serologic work-up showed positive cytoplasmicanti neutrophil cytoplasmic antibody (C-ANCA) titers and antibodies to proteinase-3 (PR-3). Myeloperoxidase-O (MPO) antibody was negative. Anti-glomerular basement membrane antibody was negative and C3/C4 levels were normal. Despite hydration, creatinine worsened to 10.42 mg/dl, and following return of the positive C-ANCA, pulse dose steroids were begun.

A kidney biopsy ( Figure 1 ) revealed cellular crescents and fibrinoid necrosis in 38/46 glomeruli, with some tubular injury. Immunofluorescence showed segmental fibrin staining the glomerular capillary loops, confirming fibrinoid necrosis. No immune complex mediated deposits were seen on electron microscopy. Interstitial fibrosis and tubular atrophy were mild.

Based on serologic and biopsy findings, a diagnosis was made of pauci-immune necrotizing and crescentic glomerulonephritis. Rituximab was initiated at 375 mg/m 2 , but the patient developed severe dyspnea and declined further doses. One dose of cyclophosphamide 7.5 mg/kg (per CYCLOPS trial dosing) was given, however hemodialysis was initiated for hyperkalemia and worsening renal function. Currently, he continues to require dialysis, while on prednisone, and with plan to repeat cyclophosphamide 2 weeks after the first dose.

With millions of doses of vaccines being administered worldwide for COVID-19, rare reports of adverse events are emerging, such as cases of minimal change disease. 1, 2 To the best of our knowledge, this is the first reported case of ANCA glomerulonephritis post COVID-19 vaccine. ANCA vasculitis has previously been reported following influenza vaccination. 3 In our case, the temporal association suggests a neutrophilic immune response to mRNA as a potential trigger. It is possible that the enhanced immune response following a second dose could be responsible for triggering PR3 antibodies. ANCA glomerulonephritis has been known to occur with certain medications, like hydralazine 4 , infections and with malignancies. 5 With medication induced ANCA vasculitis, usually MPO titers are positive. However, in hematological malignancies, PR3 titers can be positive. PR3 is a bactericidal protein expressed by neutrophilic granules. Derangements in its expression and function have been linked to hematological malignancies and pauci-immune vasculitis. Greater analysis of the immune response induced by mRNA vaccines could provide better insight into the mechanism of various autoimmune reactions, including ANCA vasculitis.

Minimal Change Disease and AKI following the Pfizer-BioNTech COVID-19 Vaccine

Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine

Vasculitis Following Influenza Vaccination: A Review of the Literature

Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine

ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives